Drug intelligence / Profile preview

Cheonggan-tang-gamibang

Development stage: Preclinical
Lead developer: Dongkwang Pharm
Administration: Oral

Overview

Cheonggan-tang-gamibang is a traditional Korean herbal medicine (TKM) formula being developed by Dongkwang Pharmaceutical for the treatment of Parkinson's disease. The drug is a modified version (gamibang) of the traditional Cheonggan-tang formula, specifically optimized for neuroprotective or symptomatic effects in Parkinson's patients. Its development has been supported by South Korean government research projects, focusing on IND-enabling preclinical studies to facilitate clinical trial entry. As a multi-component herbal extract, it likely targets multiple pathways involved in dopaminergic neuron preservation and neuroinflammation, although specific molecular targets have not been publicly disclosed by the developer.

Other names: 청간탕가미방Dongkwang Parkinson's herbal treatmentCGT-GMB

Beyond the preview

Go deeper on Cheonggan-tang-gamibang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cheonggan-tang-gamibang.

Explore the full profile